ONWARD Medical to Report 2025 Financial Results, Provide Business Update
Event summary
- ONWARD Medical will report full-year 2025 financial results on March 31, 2026.
- CEO Dave Marver will host a webcast at 2:00 p.m. CEST / 08:00 a.m. ET.
- Company's ARC-EX® System is cleared for commercial sale in the US and Europe.
- ARC-IM® and ARC-BCI are investigational products not yet commercially available.
The big picture
ONWARD Medical's upcoming financial results and business update come at a critical juncture as the company balances commercialization of its ARC-EX system with the development of next-generation neurotechnology solutions. The neurotechnology sector is increasingly focused on restoring mobility and independence, with ONWARD Medical positioning itself as a leader in spinal cord injury treatments. Investors will be watching for signs of market adoption and the company's ability to navigate regulatory hurdles for its investigational products.
What we're watching
- Regulatory Progress
- The pace at which ARC-IM and ARC-BCI advance through clinical trials and regulatory approvals.
- Commercialization Strategy
- How ONWARD Medical scales the commercial rollout of ARC-EX in the US and Europe.
- Financial Performance
- Whether 2025 results reflect sustained revenue growth or operational challenges.
Related topics